SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing significant downward pressure following an earnings report that highlighted a weak outlook and slower-than-expected turnaround in the China market, triggering a wave of analyst downgrades. Community discussion is heavily polarized between investors betting on a long-term 'buy the dip' opportunity for an iconic brand and those warning of a structural decline due to increased competition and shifting consumer preferences.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly (LLY) is trending following an FDA warning against telehealth companies for misleading marketing of compounded GLP-1 medications, a move that clarifies market expectations and increases regulatory scrutiny on the weight-loss drug space. The community is actively debating the stock's valuation, the long-term impact of potential pricing pressures, and the highly anticipated upcoming FDA approval for the company's oral obesity pill, orforglipron.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray Brands is capturing significant attention as investors speculate on upcoming cannabis rescheduling news and federal pilot programs, with sentiment sharply divided between those betting on a short squeeze and critics pointing to the company's fiscal history and management. The stock remains a high-volatility battleground where community discussions are currently fixated on potential catalysts like shifting FDA policies and the implications of the company's upcoming earnings release.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the company receives FDA approval for a higher-dose version of Wegovy, a move aimed at boosting efficacy and strengthening its competitive standing in the GLP-1 weight-loss market. The community is actively debating the stock's long-term potential, with bulls pointing to the new FDA milestone and a robust pipeline, while others remain skeptical due to pricing pressures, intense competition from Eli Lilly, and recent volatility in the broader pharmaceutical sector.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware (RH) is experiencing extreme volatility as investors weigh the impact of ongoing tariff headwinds and a struggling housing market against the potential for a short squeeze. Market participants are heavily focused on the company's mixed earnings results and management's guidance, while the community remains sharply divided over the long-term viability of their luxury retail model in a high-interest rate environment.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is currently trending as investors weigh its aggressive foundry expansion and capital structure moves against broader macroeconomic uncertainty driven by rising oil prices and geopolitical instability. The community remains deeply divided, with bulls pointing to the company's long-term manufacturing roadmap and potential for major customer announcements, while bears are focused on the stock's recent price volatility and sensitivity to regional tensions.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is attracting heavy retail attention as traders speculate on a potential short squeeze, citing its history as a volatile, low-float runner and tight share structure. While the community is sharply divided between bullish expectations of a parabolic move and warnings of a pump-and-dump scheme, discussions remain intensely focused on cost-to-borrow data and the stock's tendency for rapid, high-volume spikes.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is trending following the announcement of a massive multi-year AI infrastructure contract, fueling intense community speculation about its low-float potential to trigger a significant short squeeze.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with the community actively debating the company's debt reduction progress and the potential valuation impact of its significant holdings in Applied Digital and B. Riley Wealth. While sentiment is divided between bulls anticipating a re-rating on stronger balance sheet optics and skeptics concerned about lingering leverage and lack of clear guidance, the stock remains a focal point for those tracking a high-stakes turnaround play.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors digest the commercial launch of Yartemlea and monitor the potential for near-term milestone payments from its multi-billion dollar partnership with Novo Nordisk. Community discussion remains heavily focused on the stock's significant short interest, with many retail shareholders expressing frustration over stagnant price action while others remain bullish on the long-term value of the company's pipeline and pending European regulatory developments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Omeros (NASDAQ:OMER) Releases Earnings Results, Beats Estimates By $3.69 EPS

Omeros (NASDAQ:OMER - Get Free Report) issued its quarterly earnings data on Tuesday. The biopharmaceutical company reported $3.14 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.55) by $3.69...

<ul class="summary-bullets"><li>The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk.</li><li>The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in December.</li><li>The company is now looking forward to an approval for the therapy from the European Medicines Agency by mid-2026.</li></ul>Shares of Omeros Corporation (OMER) rose 5% after hours on Tuesday after the company expressed optimism for its deal with Danish drugmaker Novo Nordisk and regarding its other drugs.The company reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.<h2 class="st-heading-2">Omeros Corp Deal With Novo</h2>The company said that its fourth quarter results include a net gain of $237.6 million tied to the zaltenibart transaction with Novo Nordisk. Under the deal valued up to $2.1 billion, the Danish drugmaker received exclusive global rights in all indications to develop and commercialize Omeros’s zaltenibart and certain related antibodies and products.The transaction was closed in November, triggering an upfront cash payment of $240 million. The company is now eligible to receive milestone payments and tiered royalties on annual global net sales of applicable products. &nbsp;<h2 class="st-heading-2">Remaining Lineup</h2>The company’s Yartemlea was approved by the U.S. Food and Drug Administration for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy in adults and in children ages two years and older in December. Commercial distribution and sales of Yartemlea in the U.S. began in January. The drug is now being prescribed to both adult and pediatric patients across both hospital and outpatient settings, the company said, while adding that it has engaged several of its workforce to engage directly with transplant centers across the United States.The company is now looking forward to an approval for the therapy from the European Medicine Agency by mid-2026.“Following FDA approval of Yartemlea with a broad label and no boxed warning, REMS, or required vaccinations, our commercial launch is well underway, and patients who urgently need the drug are now able to access it,” said Omeros CEO Gregory A. Demopulos. “Our partnership with Novo Nordisk expands the breadth of indications being pursued for zaltenibart and has provided — and should continue to provide — substantial operating capital... These successes are expected to fuel the development of a growing portfolio of commercial products from our robust pipeline as we target positive cash flow in 2027.”<h2 class="st-heading-2">How Omeros Corp Retail Traders React?</h2>On Stocktwits, retail sentiment around OMER stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user expressed optimism for the stock rallying on the next trading day.<stembedurl>https://www.stocktwits.com/Discovergems/message/649116149</stembedurl>Another user expressed optimism for Yartemlea, particularly if it gets approval in the EU.<stembedurl>https://www.stocktwits.com/AgentMulder/message/649115278</stembedurl><a href="https://stocktwits.com/symbol/OMER">OMER stock</a> has gained 28% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mltx-stock-garners-retail-attention-on-buyout-speculation-positive-skin-condition-trial-data/cZE5EhaRIVu">MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Omeros Corporation logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

OMER Stock Surges 5% After Hours On Novo Nordisk Deal Windfall And Drug Launch Optimism

Omeros reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.

Equity

Omeros reported net income for the fourth quarter of $86.5 million, compared to a net loss of $31.4 million in the corresponding quarter of 2024.


Omeros Q4 Earnings Call Highlights

Omeros (NASDAQ:OMER) executives highlighted two major successes in the fourth quarter of 2025 that they said marked a turning point for the company: closing a $240 million upfront asset sale and...

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income...

Omeros (NASDAQ:OMER) Share Price Passes Above 200 Day Moving Average - Here's Why

Omeros (NASDAQ:OMER) Stock Passes Above Two Hundred Day Moving Average - What's Next...

Omeros Corporation to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 31, 2026

Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the fourth quarter and year ended December 31, 2025, on Tuesday, March 31, 2026 after market close...

Omeros (OMER) Projected to Post Earnings on Monday

Omeros (NASDAQ:OMER) will be releasing its Q4 2025 earnings before the market opens on Monday, March 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-3-30-omeros-co-stock...

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22...

Omeros Corporation (NASDAQ:OMER) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Omeros Corporation (NASDAQ:OMER - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five analysts that are covering the stock, MarketBeat.com reports. One equities...

Omeros (NASDAQ:OMER) Stock Crosses Above Two Hundred Day Moving Average - Here's What Happened

Omeros (NASDAQ:OMER) Stock Price Passes Above 200 Day Moving Average - Here's Why...

$OMER Q4 &#39;25 Earnings Results &amp; Recap

Omeros Corporation targets positive cash flow in 2027, expecting recent successes to fuel the development of a growing portfolio of commercial products from its robust pipeline.

Stocktwits

 Q4 '25 Earnings Results & Recap

Omeros Corporation targets positive cash flow in 2027, expecting recent successes to fuel the development of a growing portfolio of commercial products from its robust pipeline.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Thematic ETFs

Prediction Markets

OpenClaw & Agentic-Directed Trading

Tokenization

Recognizing the tool or mechanism that redefined how we trade. From prediction markets to next-gen tech, this award honors the innovation that pushed the boundaries of access and efficiency in modern finance.

Stocktwits Polls

Traders are closely tracking the commercial rollout of YARTEMLEA and early indicators of adoption to validate long-term growth.

Bulls are pointing to high short interest as a technical catalyst, arguing the stock is primed for a significant breakout move.

Optimism is building around potential new indications like ARDS that could broaden the reach of the company's proprietary technology.

Current Price	$12.24
Prev Close	$10.56
Open	$11.27
Dividend Yield	N/A
50-Day Moving Average	$11.41
Beta	1.44
Avg. Volume	972,721.84
PE Ratio	-5.23

52-Week High	$17.65
52-Week Low	$2.95
Market Capitalization	$748.71M
EPS (Annual)	-$0.0528
Price to Book	-3.36
Revenue Per Employee	$0.00

OMER
Omeros Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest OMER News

OMEROmeros Corp